東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Alzheimer's disease drug development...

Cummings, Jeffrey L.

FindBook

Google Book

Amazon

博客來

Alzheimer's disease drug development = research and development ecosystem /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Alzheimer's disease drug development/ edited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit.
其他題名:	research and development ecosystem /
其他作者:	Cummings, Jeffrey L.
出版者:	Cambridge :Cambridge University Press, : 2022.,
面頁冊數:	xx, 554 p. :ill., digital ;26 cm.
附註:	Title from publisher's bibliographic system (viewed on 07 Mar 2022).
標題:	Alzheimer's disease. -
電子資源:	https://doi.org/10.1017/9781108975759
ISBN:	9781108975759

Alzheimer's disease drug development = research and development ecosystem /
Alzheimer's disease drug developmentresearch and development ecosystem /[electronic resource] :edited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit. - Cambridge :Cambridge University Press,2022. - xx, 554 p. :ill., digital ;26 cm. - Cambridge medicine. - Cambridge medicine (Series).

Title from publisher's bibliographic system (viewed on 07 Mar 2022).

Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

ISBN: 9781108975759Subjects--Topical Terms:

588010
Alzheimer's disease.

LC Class. No.: RC523 / .A3975964 2022

Dewey Class. No.: 616.831

Alzheimer's disease drug development = research and development ecosystem /
LDR:01914nmm a2200253 a 4500 001 2324426
003 UkCbUP
005 20220314063149.0
006 m d
007 cr nn 008maaau
008 231215s2022 enk o 1 0 eng d
020 $a 9781108975759 $q (electronic bk.)
020 $a 9781108838665 $q (hardback)
035 $a CR9781108975759
040 $a UkCbUP $b eng $c UkCbUP $d GP
050 0 0 $a RC523 $b .A3975964 2022
082 0 0 $a 616.831 $2 23
090 $a RC523 $b .A478 2022
245 0 0 $a Alzheimer's disease drug development $h [electronic resource] : $b research and development ecosystem / $c edited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit.
260 $a Cambridge : $b Cambridge University Press, $c 2022.
300 $a xx, 554 p. : $b ill., digital ; $c 26 cm.
490 1 $a Cambridge medicine
500 $a Title from publisher's bibliographic system (viewed on 07 Mar 2022).
520 $a Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.
650 0 $a Alzheimer's disease. $3 588010
650 0 $a Alzheimer's disease $x Treatment. $3 660535
650 0 $a Drugs $x Research. $3 685164
650 0 $a Drug development. $3 716904
700 1 $a Cummings, Jeffrey L. $3 895422
700 1 $a Fillit, Howard. $3 3645645
700 1 $a Kinney, Jefferson W. $3 3645646
830 0 $a Cambridge medicine (Series) $3 3370358
856 4 0 $u https://doi.org/10.1017/9781108975759